Nirmatrelvir-Ritonavir for Acute COVID-19 in Patients With Cardiovascular Disease and Postacute Sequelae of SARS-CoV-2 Infection
Authors' conclusion
NMV-r in nonhospitalized vaccinated patients with pre-existing CVD with COVID-19 was associated with a reduction in PASC and health care utilization.
Study context
- Population
- Nonhospitalized, vaccinated patients with pre-existing cardiovascular disease (CVD) who developed COVID-19, December 2021 to December 2022matched cohorts
- Participants
- 26,953 vs 26,953
- Exposure
- Nirmatrelvir-ritonavir (NMV-r) vs no NMV-r within 5 days of COVID-19 diagnosis
- NMV-rn = 26,953
- non-NMV-rn = 26,953reference
- Outcome
- Presence of PASC
- Follow-up
- 30 to 90 days and 90 to 180 days after index COVID-19 infection
Methodological detailspropensity-score matched, TriNetX research network
- Propensity-score matched
- TriNetX research network
Main finding
As reported in the abstract
PASC
NMV-r
- Broad PASC, 30–90 days
- 6,925 (26%)
- Broad PASC, 90–180 days
- 6,692 (25.1%)
- Narrow PASC, 30–90 days
- 5,335 (20%)
- Narrow PASC, 90–180 days
- 5,121 (19.2%)
non-NMV-r
- Broad PASC, 30–90 days
- 8,150 (30.6%)
- Broad PASC, 90–180 days
- 8,910 (33.5%)
- Narrow PASC, 30–90 days
- 6,271 (23.6%)
- Narrow PASC, 90–180 days
- 6,964 (26.1%)
Broad PASC, 30–90 days
NMV-r6,925 (26%)
non-NMV-r8,150 (30.6%)
Broad PASC, 90–180 days
NMV-r6,692 (25.1%)
non-NMV-r8,910 (33.5%)
Narrow PASC, 30–90 days
NMV-r5,335 (20%)
non-NMV-r6,271 (23.6%)
Narrow PASC, 90–180 days
NMV-r5,121 (19.2%)
non-NMV-r6,964 (26.1%)
NMV-r vs non-NMV-rOdds ratio (95% CI)P value
Broad PASC, 30–90 days
0.80(0.76–0.82)
P < 0.001Broad PASC, 90–180 days
0.25(0.23–0.29)
P < 0.001Narrow PASC, 30–90 days
0.81(0.78–0.84)
P < 0.001Narrow PASC, 90–180 days
0.67(0.64–0.70)
P < 0.001Observational data: associations, not effects.
Original publication
Nirmatrelvir-Ritonavir for Acute COVID-19 in Patients With Cardiovascular Disease and Postacute Sequelae of SARS-CoV-2 Infection. JACC Adv. Published 26 June 2024. doi:10. 1016/ j. jacadv. 2024. 100961
Summarised from the published abstract; every number is checked against it